Literature DB >> 20819150

Elimination of hepatitis B virus surface antigen and appearance of neutralizing antibodies in chronically infected patients without viral clearance.

Z-H Zhang1, L Li, X-P Zhao, D Glebe, C M Bremer, Z-M Zhang, Y-J Tian, B-J Wang, Y Yang, W Gerlich, M Roggendorf, X Li, M Lu, D-L Yang.   

Abstract

Seroconversion from hepatitis B surface antigen (HBsAg) to antibodies against HBsAg (anti-HBs) usually indicates resolution of hepatitis B virus (HBV) infection. Here, two HBV-infected patients with seroconversion to anti-HBs were found to be persistently positive for HBeAg and HBV DNA. Immunohistology of liver biopsies confirmed the expression of HBV proteins in the liver of one patient. The neutralizing ability of anti-HBs in patient sera was demonstrated by blocking HBV infection of primary tupaia hepatocytes. Analysis of the HBsAg-encoding region of HBV isolates from patients indicated the coexistence of heterogeneous HBV genomes in patients. The majority of recombinant variant HBsAg was reactive in HBsAg assays and was able to bind to anti-HBs. Circulating immune complexes (CIC) of HBsAg in patient sera could be detected by polyethylene glycol precipitation and trypsin digestion. Thus, neutralizing anti-HBs may appear in chronic HBV carriers for long periods but does not necessarily lead to complete viral clearance.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20819150     DOI: 10.1111/j.1365-2893.2010.01322.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  9 in total

Review 1.  Genetic variation of hepatitis B virus and its significance for pathogenesis.

Authors:  Zhen-Hua Zhang; Chun-Chen Wu; Xin-Wen Chen; Xu Li; Jun Li; Meng-Ji Lu
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

2.  Broader use of hepatitis B virus vaccine: Efficacy in those who lost hepatitis B surface antigen during follow-up.

Authors:  Rakesh Kumar; Babita Agrawal
Journal:  Hepat Mon       Date:  2011-06       Impact factor: 0.660

3.  Conservative Evolution of Hepatitis B Virus Precore and Core Gene During Immune Tolerant Phase in Intrafamilial Transmission.

Authors:  Yuqian Luo; Le Zhang; Yimin Dai; Yali Hu; Biyun Xu; Yi-Hua Zhou
Journal:  Virol Sin       Date:  2020-03-02       Impact factor: 4.327

Review 4.  Immune Mechanisms Underlying Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B Patients With Viral Coinfection.

Authors:  Shuling Wu; Wei Yi; Yuanjiao Gao; Wen Deng; Xiaoyue Bi; Yanjie Lin; Liu Yang; Yao Lu; Ruyu Liu; Min Chang; Ge Shen; Leiping Hu; Lu Zhang; Minghui Li; Yao Xie
Journal:  Front Immunol       Date:  2022-05-11       Impact factor: 8.786

Review 5.  Vaccine therapies for chronic hepatitis B: can we go further?

Authors:  Yumei Wen; Xuanyi Wang; Bin Wang; Zhenhong Yuan
Journal:  Front Med       Date:  2014-01-24       Impact factor: 4.592

6.  Occult hepatitis B virus infection: influence of S protein variants.

Authors:  Zhenhua Zhang; Ling Zhang; Yu Dai; Yafei Zhang; Jun Li; Xu Li
Journal:  Virol J       Date:  2016-01-19       Impact factor: 4.099

7.  Molecular and serological characterization of hepatitis B vaccine breakthrough infections in serial samples from two plasma donors.

Authors:  Mary C Kuhns; Anne L McNamara; Vera Holzmayer; Gavin A Cloherty
Journal:  Virol J       Date:  2019-04-03       Impact factor: 4.099

Review 8.  Host Genetic Determinants of Hepatitis B Virus Infection.

Authors:  Zhenhua Zhang; Changtai Wang; Zhongping Liu; Guizhou Zou; Jun Li; Mengji Lu
Journal:  Front Genet       Date:  2019-08-13       Impact factor: 4.599

Review 9.  Toward a Functional Cure for Hepatitis B: The Rationale and Challenges for Therapeutic Targeting of the B Cell Immune Response.

Authors:  Zhiyong Ma; Ejuan Zhang; Shicheng Gao; Yong Xiong; Mengji Lu
Journal:  Front Immunol       Date:  2019-09-24       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.